Age-related macular degeneration (AMD) is one of the leading causes of vision loss among adults over 65. This condition ...

No changes in protocol recommended for LUGANO and LUCIA clinical trials – – Masked safety data continues to show no safety ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing option in all approved indications provides greater dosing ...

A wireless retinal implant called PRIMA is changing that reality by helping blind patients read and recognize faces again.

Coave Therapeutics has announced its lead gene therapy program, CoTx-10, for the treatment of retinal vascular diseases, such ...

Two researchers from DTU are among this year's recipients of the Lundbeck Foundation's Ascending Investigator grants, which ...

Cheap, versatile and packed with antioxidants, watercress is the UK's overlooked superfood. Here's what it does for your skin ...

In a first-in-human phase 1/2a clinical trial, researchers used adult stem cells to help restore vision in people with age-related macular degeneration. In the United States, age-related macular degen ...

The trial is a phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5. Recently, the company ...

Millions of Americans are or will experience some form of macular degeneration, which reduces central vision. This can make ...

ANSWER: Lp (a) (called “lipoprotein little A”) is an independent risk factor for heart disease compared to total or LDL ...

EyePoint Pharmaceuticals ( ($EYPT) ) has provided an announcement. On November 19, 2025, EyePoint Pharmaceuticals announced a positive ...